Navigation Links
MIT develops thin-film 'micro pharmacy'
Date:2/11/2008

CAMBRIDGE, Mass.--A new thin-film coating developed at MIT can deliver controlled drug doses to specific targets in the body following implantation, essentially serving as a micro pharmacy.

The film could eventually be used to deliver drugs for cancer, epilepsy, diabetes and other diseases. It is among the first drug-delivery coatings that can be remotely activated by applying a small electric field.

You can mete out what is needed, exactly when it's needed, in a systematic fashion, said Paula Hammond, the Bayer Professor of Chemical Engineering and senior author of a paper on the work appearing in the Feb. 11 issue of the Proceedings of the National Academy of Sciences.

The film, which is typically about 150 nanometers (billionths of a meter) thick, can be implanted in specific parts of the body.

The films are made from alternating layers of two materials: a negatively charged pigment and a positively charged drug molecule, or a neutral drug wrapped in a positively charged molecule.

The pigment, called Prussian Blue, sandwiches the drug molecules and holds them in place. (Part of the reason the researchers chose to work with Prussian Blue is that the FDA has already found it safe for use in humans.)

When an electrical potential is applied to the film, the Prussian Blue loses its negative charge, which causes the film to disintegrate, releasing the drugs. The amount of drug delivered and the timing of the dose can be precisely controlled by turning the voltage on and off.

The electrical signal can be remotely administered (for example, by a physician) using radio signals or other techniques that have already been developed for other biomedical devices.

The films can carry discrete packets of drugs that can be released separately, which could be especially beneficial for chemotherapy. The research team is now working on loading the films with different cancer drugs.

Eventually, devices could be designed that can automatically deliver drugs after sensing that they're needed. For example, they could release chemotherapy agents if a tumor starts to regrow, or deliver insulin if a diabetic patient has high blood sugar.

You could eventually have a signaling system with biosensors coupled with the drug delivery component, said Daniel Schmidt, a graduate student in chemical engineering and one of the lead authors of the paper.

Other lead authors are recent MIT PhD recipients Kris Wood, now a postdoctoral associate at the Broad Institute of MIT and Harvard, and Nicole Zacharia, now a postdoctoral associate at the University of Toronto.

Because the films are built layer by layer, it is easy to control their composition. They can be coated onto a surface of any size or shape, which offers more design flexibility than other drug-delivery devices that have to be microfabricated.

The drawback to microfabricated devices is that it's hard to coat the drug over a large surface area or over an area that is not planar, said Wood.

Another advantage to the films is that they are easy to mass-produce using a variety of techniques, said Hammond. These thin-film systems can be directly applied or patterned onto 3D surfaces such as medical implants.


'/>"/>

Contact: Elizabeth Thomson
thomson@mit.edu
617-258-5402
Massachusetts Institute of Technology
Source:Eurekalert

Related medicine news :

1. Capsulated Systems, Inc. Develops Long Term Local Anesthetic
2. OHSU Cancer Institute researcher develops test for targeted therapy in acute myeloid leukemia
3. Silverchair Learning Systems Updates and Develops New Courses
4. Biomarkers predict risk for invasive breast cancer years before the tumor develops
5. UCLA doctor develops new technique to treat varicose veins
6. Corey McPherson Nash Develops Case Statement for Dana-Farber Cancer Institute Capital Campaign
7. Couples more likely to divorce if spouse develops cervical or testicular cancer
8. NeoStrata Clinical Findings Reveal Benefits of Combining Glycolic Acid Peels and Targeted Home Care With Microdermabrasion for Optimized Treatment of Photodamaged Skin
9. Dblur Concludes Licensing Deal With STMicroelectronics
10. Microsoft Dynamics CRM 4.0 Users now can include Telephony and Call Recording features by adding ConversationPRO(TM) from VoiceGate, a Division of IgeaCare Systems Inc.
11. Opportunity Internationals Micro Insurance Agency to Develop and Provide Life, Health and Crop Insurance for 21 Million Poor People
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/25/2017)... ... , ... Vetoquinol USA® , a world-class developer of ... the EQUISTRO line, at this week’s Rolex Kentucky Three-Day Event in Lexington. Flexadin ... , The scientifically-developed Flexadin UCII supports the body’s normal repair of cartilage and ...
(Date:4/24/2017)... ORLANDO, FLORIDA (PRWEB) , ... April 24, 2017 ... ... of telehealth technology yesterday, featuring Bring Your Own Device (BYOD) capabilities at Telehealth ... compliment LG CNS’ pre-packaged telehealth bundles, which pairs medical devices with a pre-programmed ...
(Date:4/24/2017)... ... 24, 2017 , ... Ridgecrest Herbals makes it a point to lead the ... waste, and support renewable energy. They believe this is a crucial part of their ... for health issues, and maintain that destroying the environment in the pursuit of profit ...
(Date:4/24/2017)... ... April 24, 2017 , ... The bar for just about everything—apparel, ... inhabiting the rarified air of pop and film stardom.(1) Not to be left out ... the smile. Grins now run the gamut from being encrusted with jewels and precious ...
(Date:4/24/2017)... Washington (PRWEB) , ... April 24, 2017 , ... Sean ... OptiGrill, Oxiclean, Space Bag, Sonicare Toothbrush, Juiceman Juicer, and the George Foreman Grill (which ... perhaps any other marketer in the last 25 years. , Now, due to changes ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... , April 20, 2017 ... "Global Biosimilar Pipeline and Market Prospects: Addressing Production ... report to their offering. ... "Global Biosimilar Pipeline and Market Prospects: ... Design" provides an in-depth assessment of the current trends ...
(Date:4/20/2017)... Research and Markets has announced the addition ... Rapidly Expanding Injectables Market and Increasing Usage of Complex Biologics during ... ... rise from USD 20 Billion in 2015 to around USD 26 ... - Innovation Driven by Rapidly Expanding Injectables Market and Increasing Usage ...
(Date:4/20/2017)... --  ZappRx, Inc ., a digital health company focused on ... it closed $25 million in Series B funding led by ... Seattle that is part of a ... B round included participation from SR One , who ... (formerly Google Ventures). As part of the financing, ...
Breaking Medicine Technology: